

05 Jul 2020 |

# Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

Join us for a quick audio roundup of five useful things to know from *Scrip's* recent coverage of the global biopharmaceutical industry.

This new microcast provides a brief audio tour around *Scrip's* Five Must-Know Things, in this episode for the week ended 3 July.

On the agenda this time are coronavirus vaccines, progress in NASH, the pricing of a new epilepsy drug and one multinational's efforts to assure investors of R&D progress.

Stories mentioned in this episode:

(Also see "[Pfizer CEO Bourla Wants Profit From COVID-19 Vaccine](#)" - Scrip, 30 Jun, 2020.)

(Also see "[CanSino Coronavirus Vaccine Approved For Military Use In China](#)" - Scrip, 29 Jun, 2020.)

(Also see "[Intercept's CRL Just Continues Upheaval In NASH](#)" - Scrip, 29 Jun, 2020.)

(Also see "[Zogenix Risks Fintepla Uptake With Dravet Drug's High Price](#)" - Scrip, 28 Jun, 2020.)

(Also see "[No Looking Back For Sanofi In R&D Turnaround Quest](#)" - Scrip, 26 Jun, 2020.)

[Click here to explore this interactive content online](#) ✨